tagrisso
astrazeneca ab - osimertinib mesilate - karcinóma, nem kissejtes tüdő - egyéb daganatellenes szerek, a protein kináz inhibitorok - tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations- the first-line treatment of adult patients nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc. tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations. - the first-line treatment of adult patients with locally advanced or metastatic nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc.
hunperdal-richter 1 mg filmtabletta
richter gedeon nyrt. - riszperidon -
hunperdal-richter 2 mg filmtabletta
richter gedeon nyrt. - riszperidon -
hunperdal-richter 3 mg filmtabletta
richter gedeon nyrt. - riszperidon -
hunperdal-richter 4 mg filmtabletta
richter gedeon nyrt. - riszperidon -
hunperdal-richter 0,5 mg filmtabletta
richter gedeon nyrt. - riszperidon -
topiramate arrow 25 mg filmtabletta
arrow generics ltd. - topiramát -
topiramate arrow 50 mg filmtabletta
arrow generics ltd. - topiramát -
topiramate arrow 100 mg filmtabletta
arrow generics ltd. - topiramát -
topiramate arrow 200 mg filmtabletta
arrow generics ltd. - topiramát -